Press Release: Surfix supports developments towards new colorectal cancer screening with NKI and CRCbioscreen

Surfix Diagnostics, the Netherlands Cancer Institute and CRCbioscreen join forces to validate biomarkers for colorectal cancer screening

Amsterdam and Wageningen, Netherlands, July 10, 2024: Today, Surfix Diagnostics alongside the Netherlands Cancer Institute (NKI) and CRCbioscreen, announce a collaboration aimed at enhancing colorectal cancer (CRC) screening methods. This project is set to leverage Surfix Diagnostics' advanced photonic diagnostic platform and novel biomarkers targeting molecularly-defined high risk precursor lesions and cancer discovered by NKI. This project is, supported by a PPP grant from the TKI-program Life Sciences & Health of Health-Holland, marking a significant step forward in non-invasive colorectal cancer early detection. 

The full text of the press release can be found here: Life Science Newswire